Bibliography
- Roberts N, Martin J, Kinchington D, Rational design of peptide-based HIV proteinase inhibitors. Science 1990;248:358-61
- Erickson J, Neidhart D, VanDrie J, Design, activity and 2.8 Å crystal structure of a C2 symmetric inhibitor complexed to HIV-1 protease. Science 1990;249:527-33
- Hartman GD, Egbertson MS, Halczenko W, Non-peptide fibrinogen receptor antagonists. 1. Discovery and design of exosite inhibitors. J Med Chem 1992;35:4649-52
- Dorsey BD, Levin RB, McDaniel SL, L-735,524: the design of a potent and orally available HIV inhibitor. J Med Chem 1994;37:3443-51
- Oprea TI, Matter H. Integrating virtual screening in lead discovery. Curr Opin Chem Biol 2004;8:349-58
- Shoichet BK. Virtual screening of chemical libraries. Nature 2004;432:862-5
- Nicholls A, McGaughey GB, Sheridan RP, Molecular shape and medicinal chemistry: a perspective. J Med Chem 2010;53:3862-86
- Hardy LW, Malikayil A. The impact of structure-guided drug design on clinical agents. Curr Drug Discov 2003;3:15-20
- Perola E. An analysis of the binding efficiencies of drugs and their leads in successful drug discovery programs. J Med Chem 2010;53(7):2986-97
- Anderson AC. The process of structure-based drug design. Chem Biol 2003;10:787-97
- Jencks WP. On the attribution and additivity of binding energies. Proc Natl Acad Sci USA 1981;78:4046-50
- Shuker SB, Hajduk PJ, Meadows RP, Fesik SW. Discovering high-affinity ligands for proteins: SAR by NMR. Science 1996;274(5292):1531-4
- Jhoti H, Cleasby A, Verdonk M, Williams G. Fragment-based screening using X-ray crystallography and NMR spectroscopy. Curr Opin Chem Biol 2007;11:485-93
- Swayze EE, Jefferson EA, Sannes-Lowery KA, SAR by MS: a ligand based technique for drug lead discovery against structured RNA targets. J Med Chem 2002;45:3816-19
- Perspicace S, Banner D, Benz J, Fragment-based screening using surface plasmon resonance technology. J Biomol Screen 2009;14:337-49
- Erlanson DA, Wells JA, Braisted AC. Tethering: fragment-based discovery. Annual Rev Biophys Biomol Struct 2004;33:199-223
- Matthews TP, Klair S, Burns S, Identification of inhibitors of checkpoint kinase 1 through template screening. J Med Chem 2009;52(15):4810-19
- Ward WH, Holdgate GA. Isothermal titration calorimetry in drug discovery. Prog Med Chem 2001;38:309-76
- Hajduk PJ, Greer J. A decade of fragment-based drug design: strategic advances and lessons learned. Nat Rev Drug Discov 2007;6(3):211-19
- Orita M, Warizaya M, Amano Y, Advances in fragment-based drug discovery platforms. Expert Opin Drug Discov 2009;4(11):1125-44
- Congreve M, Chessari G, Tisi D, Woodhead AJ. Recent developments in fragment-based drug discovery. J Med Chem 2008;51(13):3662-80
- Alex AA, Flocco MM. Fragment-based drug discovery: what has it achieved so far? Curr Top Med Chem 2007;7(16):1544-67
- Chessari G, Woodhead AJ. From fragment to clinical candidate – a historical perspective. Drug Discov Today 2009;14(13/14):668-675
- Davies AM, Keeling DJ, Steele J, Components of successful lead generation. Curr Top Med Chem 2005;5:421-39
- Boehm H-J, Boehringer M, Bur D, Novel inhibitors of DNA gyrase: 3D structure based biased needle screening, hit validation by biophysical methods, and 3D guided optimization. A promising alternative to random screening. J Med Chem 2000;43:2664-74
- Edwards PD, Albert JS, Sylvester M, Application of fragment-based lead generation to the discovery of novel, cyclic amidine beta secretase inhibitors with nanomolar potency, cellular activity, and high ligand efficiency. J Med Chem 2007;50:5912-25
- Gribbon P, Sewing A. High-throughput drug discovery: what can we expect from HTS? Drug Discov Today 2005;10:17-22
- Bohacek RS, McMartin C, Guida WC. The art and practice of structure-based drug design: a molecular modeling perspective. Med Res Rev 1996;16:3-50
- Martin YC. Challenges and prospects for computational aids to molecular diversity. Prospec Drug Discov Des 1997;7-8:159-172
- Hann MM, Leach AR, Harper G. Molecular complexity and its impact on the probability of finding leads for drug discovery. J Chem Inf Comput Sci 2001;41:856-64
- Fink T, Bruggesser H, Reymond JL. Virtual exploration of the small-molecule chemical universe below 160 Daltons. Angew Chem Int Ed Engl 2005;44:1504-8
- Schuffenhauer A, Ruedisser S, Marzinzik A, Library design for fragment based screening. Curr Top Med Chem 2005;5:751-62
- Pellechia M, Sem DS, Wuthrich K. NMR in drug discovery. Nature Rev Drug Discov 2002;1:211-19
- Kuhn P, Wilson K, Patch MG, Stevens RC. The genesis of high-throughput structure-based drug discovery using protein crystallography. Curr Opin Chem Biol 2002;6:704-10
- Blundel TL, Jhoti H, Abell C. High-throughput crystallography for lead discovery in drug design. Nat Rev Drug Discov 2002;1:45-54
- Moore Jr WR. Maximizing discovery efficiency with a computationally driven fragment approach. Curr Opin Drug Discov Devel 2005;8(3):355-64
- Vadja S, Guarnieri F. Characterization of protein–ligand interaction sites using experimental and computational methods. Curr Opin Drug Discov Devel 2006;9:354-62
- Kunz ID, Chen K, Sharp KA, Kollman PA. The maximal affinity of ligands. Proc Natl Acad Sci USA 1999;96(18):9997-10002
- Hopkins AL, Groom CR, Alex A. Ligand efficiency: a useful metric for lead selection. Drug Discov Today 2004;9(10):430-1
- Abad-Zapatero C, Metz JM. Ligand efficiency indices as guideposts for drug discovery. Drug Discov Today 2005;10(7):464-9
- Reynolds CH, Bembenek SD, Tounge BA. The role of molecular size in ligand efficiency. Bioorg Med Chem Lett 2007;17(15):4258-61
- Reynolds CH, Tounge BA, Bembenek SD. Ligand binding efficiency: trends, physical basis, and implications. J Med Chem 2008;51(8):2432-8
- Abad-Zapatero C. Ligand efficiency indices for effective drug discovery. Expert Opin Drug Discov 2007;2(4):469-88
- Keseru GM, Makara GM. The influence of lead discovery strategies on the properties of drug candidates. Nat Rev Drug Discov 2009;8(3):203-12
- Leeson PD, Springthorpe B. The influence of drug-like concepts on decision-making in medicinal chemistry. Nat Rev Drug Discov 2007;6:881-90
- Freire E. Do enthalpy and entropy distinguish first in class from best in class? Drug Discov Today 2008;13(19/20):869-874
- Pellecchia M. Fragment-based drug discovery takes a virtual turn. Nat Chem Biol 2009;5(5):274-5
- Rees DC, Congreve M, Murray CW, Carr R. Fragment-based lead discovery. Nat Rev Drug Discov 2004;3:660-72
- Fersht AR, Shi JP, Knill-Jones J Hydrogen bonding and biological specificity analysed by protein engineering. Nature 1985;314:235-8
- Davis AM, Teague SJ, Kleywegt GJ. Applications and limitations of x-ray crystallographic data in structure-based ligand and drug design. Angew Chem Int Ed 2003;42:2718-38
- Mountain V. Astex, Structural Genomix, and Syrrx. I can see clearly now: structural biology and drug discovery. Chem Biol 2003;10:95-8
- Sharf A, Jhoti H. High-throughput crystallography to enhance drug discovery. Curr Opin Chem Biol 2003;7:340-5
- Protein Data Bank. Available from: http://www.rcsb.org/pdb
- Mattos C, Ringe D. Locating and characterizing binding sites on proteins. Nat Biotechnol 1996;14:595-9
- Mattos C, Ringe D. Proteins in organic solvents. Curr Opin Struct Biol 2001;11:761-4
- Sali A, Overington JP. Derivation of rules for comparative protein modeling from a database of protein structure alignments. Protein Sci 1994;3:1582-96
- Sali A, Potterton L, Yuan F, Evaluation of comparative protein modeling by MODELLER. Proteins 1995;23:318-26
- Cardozo T, Totrov MM, Abagyan RA. Homology modeling by the ICM method. Proteins 1995;23:403-14
- Diller DJ, Li R. Kinases, homology models, and high throughput docking. J Med Chem 2003;46(22):4638-47
- Hillisch A, Pineda LF, Hilgenfeld R. Utility of homology models in the drug discovery process. Drug Discov Today 2004;9(15):659-69
- Lee T, Ma W, Zhang X, BCR-ABL alternative splicing as a common mechanism for imitanib resistance: evidence from molecular dynamics simulations. Mol Cancer Ther 2008;12:3834-41
- Subramanian J, Sharma S, B-Rao C. Modeling and selection of flexible proteins for structure-based drug design: backbone and side chain movements in p38 MAPK. Chem Med Chem 2008;3:336-44
- Kufareva I, Abagyan R. Type-II kinase inhibitor docking, screening, and profiling using modified structures of active kinase states. J Med Chem 2008;51(24):7921-32
- Traxler P, Furet P, Mett H, Design and synthesis of novel tyrosine kinase inhibitors using a pharmacophore model of the ATP-binding site of the EGF-R. J Pharm Belg 1997;52:88-96
- Sudbeck EA, Liu XP, Narla RK, Structure-based design of specific inhibitors of Janus kinase 3 as apoptosis-inducing antileukemic agents. Clin Cancer Res 1999;5:1569-82
- Vankayalapati H, Bearss DJ, Saldanha JW, Targeting aurora 2 kinase in oncogenesis: a structural bioinformatics approach to target validation and rational drug design. Mol Cancer Ther 2003;2:283-94
- Hillisch A, Peters O, Kosemund D, Dissecting physiological roles of estrogen receptor alpha and beta with potent selective ligands from structure-based design. Mol Endocrinol 2004;18:1599-609
- Nayeem A, Sitkoff D, Krystek Jr S. A comparative study of available software for high-accuracy homology modeling: from sequence alignments to structural models. Protein Sci 2006;15:808-24
- Hansen RW. The pharmaceutical development process: estimates of current development costs and times and effects of regulatory changes. In: Chien RI, editor. Issues in pharmaceutical economics. Lexington Books, Lexington, MA; 1979. p. 151-87
- DiMasi JA, Hansen RW, Grabowski HG, Lasagna L. Cost of innovation in the pharmaceutical industry. J Health Econ 1991;10:107-42
- DiMasi JA, Hansen RW, Grabowski HG. The price of innovation: new estimates of drug development costs. J Health Econ 2003;22:151-85
- Aronovitz LG, Redican-Bigott G, Hormozi S, New drug development: science, business, regulatory, and intellectual property issues cited as hampering drug development efforts. Report GAO-07-49; 2006
- Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 1997;23:3-25
- Veber DF, Johnson SR, Cheng HY, Molecular properties that influence the oral bioavailability of drug candidates. J Med Chem 2002;45:2615-23
- Congreve M, Carr R, Murray C, Jhoti H. A “rule of three” for fragment-based lead discovery? Drug Discov Today 2003;8:876-7
- Lepre CA. Library design for NMR-based screening. Drug Discov Today 2001;6:133-40
- Jacoby E, Davies J, Blommers MJJ. Design of small molecule libraries for NMR screening and other applications in drug discovery. Curr Top Med Chem 2003;3:11-23
- Comprehensive Medicinal Chemistry. Available from Elsevier B.V., Amsterdam, Netherlands; 2006
- MDL Drug Data Report. Available from Symyx Technologies Inc., San Ramon, CA, USA; 2010
- World Drug Index. Available from Thomson Reuters, New York, NY, USA; 2010
- Siegal G, Eiso AB, Schultz J. Integration of fragment screening and library design. Drug Discov Today 2007;12(23/24):1032-1039
- Vieth M, Siegel MG, Higgs RE, Characteristic physical properties and structural fragments of marketed oral drugs. J Med Chem 2004;47:224-32
- Lepre CA, Moore JM, Peng JW. Theory and applications of NMR-based screening in pharmaceutical research. Chem Rev 2004;104:3641-76
- Lewell XQ, Judd DB, Watson SP, Hann MM. RECAP-retrosynthetic combinatorial analysis procedure: a powerful new technique for identifying privileged molecular fragments with useful applications in combinatorial chemistry. J Chem Inf Comput Sci 1998;38:511-22
- Schneider G, Bohm H-J. Virtual screening and fast automated docking methods. Drug Disc Today 2002;7(1):64-70
- Jorgensen WL. The many roles of computation in drug discovery. Science 2004;303:1813-18
- Schneider G, Fechner U. Computer-based de novo design of drug-like molecules. Nat Rev Drug Discov 2004;4:649-63
- Zoete V, Grosdidier A, Michielin O. Docking, virtual high throughput screening and in silico fragment-based drug design. J Cell Mol Med 2009;13(2):238-48
- Tembe BL, McCammon JA. Ligand-receptor interactions. Comput Chem 1984;8:281-3
- Gilson GL, Given JA, Bush BL, McCammon JA. The statistical-thermodynamic basis for computation of binding affinities: a critical review. Biophys J 1997;72:1047-69
- Jorgensen WL. Free energy calculations. A breakthrough for modeling organic chemistry in solution. Acc Chem Res 1989;22:184-9
- Kollman PA. Free energy calculations: applications to chemical and biochemical phenomena. Chem Rev 1993;93:2395-417
- Aqvist J, Medina C, Samuelsson JE. A new method for predicting binding affinity in computer-aided drug design. Protein Eng 1994;7:385-91
- Wang J, Morin P, Wang W, Kollman PA. Use of MM-PBSA in reproducing the binding free energies to HIV-1 RT of TIBO derivatives and predicting the binding mode to HIV-1 RT of Efavirenz by docking and MM-PBSA. J Am Chem Soc 2001;123:5221-30
- Chang C-E, Gilson MK. Free energy, entropy, and induced fit in host-guest recognition: calculations with second-generation mining minima algorithm. J Am Chem Soc 2004;126:13156-64
- Weis A, Katebzadeh K, Soderhjelm P, Ligand affinities predicted with the MM/PBSA method: dependence on the simulation method and the force field. J Med Chem 2006;49:6596-606
- Guarnieri F. Computational protein probing to identify binding sites. US6735530; 2004
- Clark M, Guarnieri F, Shkurko I, Wiseman J. Grand canonical monte carlo simulation of ligand-protein binding. J Chem Inf Model 2006;46:231-42
- Clark M, Meshkat S, Wiseman JS. Grand canonical free-energy calculations of protein-ligand binding. J Chem Inf Model 2009;49:934-43
- Guarnieri F, Mezei M. Simulated annealing of chemical potential: a general procedure for locating bound waters. Application to the study of the differential hydration propensities of the major and minor grooves of DNA. J Am Chem Soc 1996;118:8493-4
- Clark M, Meshkat S, Talbot GT, Fragment-based computation of binding free energy by systematic sampling. J Chem Inf Model 2009;49:1901-13
- Nishibata Y, Itai A. Automatic creation of drug candidate structures based on receptor structure. Starting point for artificial lead generation. Tetrahedron 1991;47:8985-90
- Miranker A, Karplus M. Functionality maps of binding sites: a multiple copy simultaneous search method. Proteins 1991;11:29-34
- Eisen MB, Wiley DC, Karplus M, Hubbard RE. HOOK: a program for finding novel molecular architectures that satisfy the chemical and steric requirements of a macromolecule binding site. Proteins 1994;19:199-221
- Pearlman DA, Murcko MA. CONCERTS: dynamic connection of fragments as an approach to de novo ligand design. J Med Chem 1996;39:1651-63
- Boehm H-J. The computer program LUDI: a new simple method for the de-novo design of enzyme inhibitors. J Comp Aided Mol Des 1992;6:61-78
- Clark DE, Frenkel D, Levy SA, PRO-LIGAND: an approach to denovo molecular design. 1. Application to the design of organic molecules. J Comput Aided Mol Des 1995;9:13-32
- Wang R, Gao Y, Lai L. LigBuilder: a multi-purpose program for structure-based drug design. J Mol Model 2000;6:498-516
- DeWitte RS, Shakhnovich EI. SMoG de novo design method based on simple, fast, and accurate free energy estimates. 1. Methodology and supporting evidence. J Am Chem Soc 1996;118:11733-44
- Sousa SF, Fernandes PA, Ramos MJ. Protein-ligand docking: current status and future challenges. Proteins 2006;65:15-26
- Moitessier N, Englebienne P, Lee D, Towards the development of universal, fast and highly accurate docking/scoring methods: a long way to go. Br J Pharmacol 2008;153:S7-26
- Kunz ID, Blaney JM, Oatley SJ, A geometric approach to macromolecule-ligand interactions. J Mol Biol 1982;161:269-88
- Honma T. Recent advances in de novo design strategy for practical lead identification. Med Res Rev 2003;23(5):606-32
- Warren GL, Andrews CW, Capelli A-M, A critical assessment of docking programs and scoring functions. J Med Chem 2006;49:5912-31
- Hopkins AL, Groom CR. The druggable genome. Nat Rev Drug Discov 2002;1:727-30
- Fauman EB, Hopkins AL, Groom CR. Structural bioinformatics in drug discovery. In: Weissig H, Bourne P, editors. Structural bioinformatics. Wiley-Liss, Hoboken, NJ; 2003. p. 477-98
- Hajduk PJ, Huth JR, Tse C. Predicting protein druggability. Drug Discov Today 2005;10(23/24):1675-1682
- Halgren TA. Identifying and characterizing binding sites and assessing druggability. J Chem Inf Model 2009;49(2):377-89
- Hajduk PJ, Huth JR, Fesik SW. Druggability indices for protein targets derived from NMR-based screening data. J Med Chem 2005;48:2518-25
- Cheng AC, Coleman RG, Smyth KT, Structure-based maximal affinity model predicts small-molecule druggability. Nat Biotechnol 2007;25(1):71-5
- Schmidtke P, Barril X. Understanding and predicting druggability. A high-throughput method for detection of drug binding sites. J Med Chem 2010;53(15):5858-67
- Landon MR, Lancia DR, Yu J, Identification of hot spots within druggable binding regions by computational solvent mapping of proteins. J Med Chem 2007;50:1231-40
- Landon MR, Lieberman RL, Hoang QQ, Detection of ligand binding hot spots on protein surfaces via fragment-based methods: application to DJ-1 and glucocerebrosidase. J Comput Aided Mol Des 2009;23:491-500
- Seco J, Luque FJ, Barril X. Binding site detection and druggability index from first principles. J Med Chem 2009;52:2363-71
- Available Chemicals Directory. Available from Symyx Technology Inc., San Romon, CA, USA; 2010
- Bohm H-J, Banner DW, Weber L. Combinatorial docking and combinatorial chemistry: design of potent non-peptide thrombin inhibitors. J Comput Aided Mol Des 1999;13:51-6
- Rummey C, Nordhoff S, Thiemann M, Metz G. In silico fragment-based discovery of DPP-IV S1 pocket binders. Bioorg Med Chem Lett 2006;16:1405-9
- Nordhoff S, Cerezo-Galvez S, Feurer A, The reversed binding of beta-phenethylamine inhibitors of DPP-IV: X-ray structures and properties of novel fragment and elaborated inhibitors. Bioorg Med Chem Lett 2006;16:1744-8
- Warner SL, Bashyam S, Vankayalapati H, Identification of a lead small-molecule inhibitor of the aurora kinases using a structure-assisted, fragment-based approach. Mol Cancer Ther 2006;5:1764-73
- Regan J, Bretflelder S, Cirillo P, Pyrazole urea-based inhibitors of p38 MAP kinase: from lead compound to clinical candidate. J Med Chem 2002;45:2994-3008
- Liu B. A potent and selective p38 allosteric inhibitor: virtual fragment-based design, synthesis and biological study. Presentation. ACS Meeting; Washington DC; 29 August 2009
- Chen Y, Shoichet BK. Molecular docking and ligand specificity in fragment-based inhibitor discovery. Nat Chem Biol 2009;5(5):358-64
- ZINC small molecule database. Available from: http://zinc.docking.org
- Sandor M, Kiss R, Keseru GM. Virtual fragment docking by Glide: a validation study on 190 protein-fragment complexes. J Chem Inf Model 2010;50(6):1165-72
- McDaughey GM, Culberson JC, Feuston BP, Scoring of KDR kinase inhibitors: using interaction energy as a guide for ranking. Mol Divers 2006;10:341-7
- Young T, Abel R, Kim B, Motifs for molecular recognition exploiting hydrophobic enclosure in protein-ligand binding. Proc Nat Acad Sci 2007;104(3):808-13
- Robinson DD, Sherman W, Farid R. Understanding kinase selectivity through energetic analysis of binding site waters. Chem Med Chem 2010;5:618-27
- Sherman W, Day T, Jacobson MP, Novel procedure for modeling ligand/receptor induced fit effects. J Med Chem 2006;49:534-53
- Beier C, Zacharias M. Tackling the challenges posed by target flexibility in drug design. Expert Opin Drug Discov 2010;5(4):347-59
- Orozco M, Luque FJ. Theoretical methods for the description of the solvent effect in biomolecular systems. Chem Rev 2000;100(11):4187-225
- Jones S, Thornton JM. Principles of protein-protein interactions. Proc Natl Acad Sci USA 1996;93:13-20
- Fry D, Vassilev L. Targeting protein-protein interactions for cancer therapy. J Mol Med 2005;83:955-63
- Hopkins AL, Groom CR. The druggable genome. Nat Rev Drug Discov 2002;1:727-30
- Wells JA, McClendon CL. Reaching for high-hanging fruit in drug discovery at protein-protein interfaces. Nature 2007;450:1001-9
- Fry DC. Drug-like inhibitors of protein-protein interactions: a structural examination of effective protein mimicry. Curr Prot Pept Sci 2008;9:240-7
- Zinzalla G, Thurston DE. Targeting protein-protein interactions for therapeutic intervention: a challenge for the future. Future Med Chem 2009;1(1):65-93
- Vucic D, Fairbrother WJ. The inhibitor of apoptosis proteins as therapeutic targets in cancer. Clin Cancer Res 2007;13(20):5995-6000
- FDA Clinical trials Available from: https://clinicaltrials.gov
- Huang J-W, Zhang Z, Wu B, Fragment-based design of small molecule X-linked inhibitor of apoptosis protein inhibitors. J Med Chem 2008;51:7111-18
- Congreve M, Marshall F. The impact of GPCR structures on pharmacology and structure-based drug design. Br J Pharmacol 2010;159:986-96
- Carlsson J, Yoo L, Gao Z-G, Structure-based discovery of A2A adenosine receptor ligands. J Med Chem 2010;53:3748-55
- Jaakola VP, Griffith MT, Hanson MA, The 2.6 angstrom crystal structure of a human A(2A) adenosine receptor bound to an antagonist. Science 2008;322:1211-17
- Aronovitz LG, Redican-Bigott G, Hormozi S, New drug development: science, business, regulatory, and intellectual property issues cited as hampering drug development efforts. Report to congessional requesters, GAO-07-49 USA; 2006
- Podolyan Y, Walters MA, Karypis G. Assessing synthetic accessibility of chemical compounds using machine learning methods. J Chem Inf Model 2010;50(6):979-91
- Law J, Zsoldos Z, Simon A, Route designer: a retrosynthetic analysis tool utilizing automated retrosynthetic rule generation. J Chem Inf Model 2009;49(3):593-602